NIST seeks input on Trusted Identities

The U.S. Department of Commerce and National Institute of Standards and Technology is conducting a review of governance models for a governance body to administer the processes for policy and standards adoption for the Identity Ecosystem Framework in accordance with the National Strategy for Trusted Identities in Cyberspace (NSTIC).

Referring to the governance body as a steering group, the department is seeking public comment from all stakeholders, including the commercial, academic and civil society sectors, and consumer and privacy advocates on potential models, in the form of recommendations and key assumptions in the formation and structure of the steering group, according to a notice of inquiry.

The Department seeks to learn and understand approaches for:

  • The structure and functions of a persistent and sustainable private sector-led steering group; and
  • The initial establishment of the steering group.

“This notice specifically seeks comment on the structures and processes for Identity Ecosystem governance. This notice does not solicit comments or advice on the policies that will be chosen by the steering group or specific issues such as accreditation or trustmark schemes, which will be considered by the steering group at a later date,” the notice states.

Responses to this notice will serve only as input for a departmental report of government recommendations for establishing the NSTIC steering group, the notice clarified.

Comments are due on or before July 22. Click here to see the notice.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.